VivoSeq
Oncology

Liver Metastases

0

Pipeline Programs↗

12

Active Trials↗

5

Companies Involved↗

Liver Metastases is an early-stage landscape with 0 programs across 5 companies. The most active players are Navidea Biopharmaceuticals, NS Pharma, EXACT Therapeutics AS.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

62/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Navidea Biopharmaceuticals

0 programs

PreclinicalNS Pharma logo

NS Pharma

0 programs

PreclinicalE

EXACT Therapeutics AS

0 programs

PreclinicalAmgen logo

Amgen

0 programs

PreclinicalA

Anza Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

56

clinical trials

Completed21 · 38%
Unknown status10 · 18%
Terminated8 · 14%
Recruiting8 · 14%
Withdrawn4 · 7%
Not yet recruiting2 · 4%
Other3 · 5%

Clinical Trials

Trial Activity

56 trials

SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
Recruiting·FFujian Cancer Hospital·Phase 2·NCT06787183·42 enrolled
CapTemY90 for Grade 2/3 NET Liver Metastases
Recruiting·—·Phase 2·NCT04339036·70 enrolled
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
Recruiting·UUniversity Hospital, Bordeaux·Phase 2·NCT04837885·23 enrolled
INFINITIVE: ImmuNotherapy For PatIeNts wIth colorecTal LIVer MEtastases
Recruiting·NNorthwell Health·Phase 1·NCT07172282·10 enrolled
ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05062317·120 enrolled
Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
Recruiting·—·Phase 1·NCT05240950·18 enrolled
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
Recruiting·National Cancer Centre, Singapore·Phase 2·NCT04912765·60 enrolled
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
Recruiting·—·Phase 1/2·NCT06311851·40 enrolled
HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.
Active, not recruiting·OOslo University Hospital·Phase 2·NCT04898504·45 enrolled
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Not yet recruiting·—·Phase 1/2·NCT07277322·24 enrolled
Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases
Not yet recruiting·IImmunophotonics, Inc.·Phase 2/3·NCT07321847·717 enrolled
Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
Enrolling by invitation·FFudan University·Phase 2·NCT07441369·16 enrolled
Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases
Completed·—·Phase 2/3·NCT03590119·26 enrolled
Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases
Completed·SStanford University·N/A·NCT01631318·34 enrolled
Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors
Completed·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT01678664·74 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)